Trial Profile
A Multicentre, Randomised, Open-label, Phase 2 trial of mifamurtide combined with post-operative chemotherapy for newly diagnosed high risk osteosarcoma patients (metastatic osteosarcoma at diagnosis or localised disease with poor histological response)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Mifamurtide (Primary) ; Cisplatin; Doxorubicin; Etoposide; Ifosfamide; Methotrexate
- Indications Osteosarcoma
- Focus Therapeutic Use
- Acronyms SARCOME13
- 01 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 08 Dec 2022 Planned End Date changed from 1 Oct 2028 to 1 Oct 2033.
- 08 Dec 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Oct 2024.